Shots: Takeda has signed an agreement with Celltrion to divest 18 select OTC and prescription pharmaceutical assets exclusively commercialized in the Asia Pacific under which Takeda will receive $266M as up front in cash and up to $12M as milestones. The transaction is expected to be closed in H2’20 Additionally, the two companies signed manufacturing […]Read More
